Obesity drugmakers expand trials to children as young as 6

Pharmaceutical companies are initiating clinical trials for obesity drugs in pediatric populations as young as six years old, expanding the market beyond adults. The move signals a strategic push to capture early intervention, though long-term safety and efficacy data in children remain limited. This development could reshape pediatric obesity treatment standards and drive significant revenue growth for drugmakers.